Infliximab is a recombinant protein that has the potential to induce humoral immune responses and lead to anti-drug antibody formation; a major cause of loss of response.
These Anti-drug antibodies bind and neutralise the TNFα inhibitors accelerating their clearance and reduces the efficacy of the drugs. Monitoring the efficacy of TNFα inhibitors may help clinicians schedule a successful individualised treatment strategy for their patients.
Free Anti-Infliximab Antibody ELISA
Free anti-drug antibody ELISAs (“drug sensitive assays”) enable the detection of anti-drug antibodies that are not bound to other proteins or therapeutic drugs only. When the dosage of infliximab is intensified it has been shown that anti-drug antibodies are not cleared immediately and can actually be masked by the drug level for long periods. This is an important consideration for cost effectiveness of dosage intensification and risk of treatment reactions.
When the drug level is low (undetectable or subtherapeutic) detecting high levels of free anti-infliximab antibodies in patients may indicate poorer long term outcomes and suggest the need to switch drug.
IDKmonitor® Infliximab Free Anti-drug Antibody ELISA is a qualitative assay that detects human antibodies against infliximab in EDTA plasma and serum samples by capturing the anti-infliximab antibodies on the microplate which is coated with infliximab F(ab)2 fragments.
Detects free anti-Infliximab Antibodies in Serum and Plasma
Microplate coated with highly specific Infliximab F(ab)2 fragments
1 calibrator, 2 controls
Capacity for 45 samples in duplicate
Automatable on ELISA automates (e.g. Dynex D2)
Supports the investigation of primary non response and loss of response to Infliximab
Drug sensitive assay only detects free anti-infliximab antibodies (those not bound to infliximab)
Helps predict long term outcome of disease in patients with sub-therapeutic infliximab levels
Applicable to Gastroenterology, Rheumatology